Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.54 Million SEK | -61.56% |
| 2022 | 27.43 Million SEK | 220.57% |
| 2021 | 8.55 Million SEK | -24.03% |
| 2020 | 11.26 Million SEK | 203.62% |
| 2019 | 3.71 Million SEK | 365.29% |
| 2018 | 797.37 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 10.54 Million SEK | -51.01% |
| 2023 Q3 | 21.52 Million SEK | 23.28% |
| 2023 Q1 | 49.24 Million SEK | 79.52% |
| 2023 Q2 | 17.46 Million SEK | -64.54% |
| 2023 FY | 10.54 Million SEK | -61.56% |
| 2022 Q1 | 8.27 Million SEK | -3.27% |
| 2022 Q4 | 27.43 Million SEK | 8.08% |
| 2022 FY | 27.43 Million SEK | 220.57% |
| 2022 Q3 | 25.38 Million SEK | 65.98% |
| 2022 Q2 | 15.29 Million SEK | 84.74% |
| 2021 Q4 | 8.55 Million SEK | 66.08% |
| 2021 FY | 8.55 Million SEK | -24.03% |
| 2021 Q3 | 5.15 Million SEK | -47.13% |
| 2021 Q1 | 7.16 Million SEK | -36.36% |
| 2021 Q2 | 9.74 Million SEK | 35.95% |
| 2020 Q4 | 11.26 Million SEK | 0.0% |
| 2020 FY | 11.26 Million SEK | 203.62% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 3.71 Million SEK | 365.29% |
| 2018 FY | 797.37 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 90.106% |
| Ziccum AB (publ) | 6.38 Million SEK | -65.106% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -347.096% |
| BioArctic AB (publ) | 139.5 Million SEK | 92.44% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 69.52% |
| Mendus AB (publ) | 51.22 Million SEK | 79.41% |
| Genovis AB (publ.) | 98.04 Million SEK | 89.243% |
| Intervacc AB (publ) | 21.68 Million SEK | 51.351% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 60.51% |
| Active Biotech AB (publ) | 13.4 Million SEK | 21.291% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 91.493% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 34.56% |
| Aptahem AB (publ) | 8.99 Million SEK | -17.217% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 74.187% |
| Kancera AB (publ) | 17.97 Million SEK | 41.334% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 77.161% |
| Fluicell AB (publ) | 8.91 Million SEK | -18.306% |
| Saniona AB (publ) | 86.08 Million SEK | 87.748% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -104.478% |
| Biovica International AB (publ) | 34.76 Million SEK | 69.664% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 9.607% |
| AcouSort AB (publ) | 10.37 Million SEK | -1.628% |
| Xintela AB (publ) | 14.01 Million SEK | 24.745% |
| Abliva AB (publ) | 16.78 Million SEK | 37.149% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 95.085% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 8.834% |
| OncoZenge AB (publ) | 1.69 Million SEK | -520.777% |
| 2cureX AB (publ) | 2.93 Million SEK | -259.353% |
| CombiGene AB (publ) | 4.15 Million SEK | -153.778% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -138.296% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.326% |
| Camurus AB (publ) | 414.81 Million SEK | 97.457% |
| Corline Biomedical AB | 6.78 Million SEK | -55.354% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 82.81% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 44.965% |
| I-Tech AB | 16.2 Million SEK | 34.915% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.111% |
| Cyxone AB (publ) | 4.69 Million SEK | -124.691% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 20.866% |
| Biosergen AB | 5.08 Million SEK | -107.414% |
| Cantargia AB (publ) | 54.97 Million SEK | 80.813% |
| NextCell Pharma AB | 13.68 Million SEK | 22.953% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 85.321% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 23.415% |
| Nanologica AB (publ) | 79.32 Million SEK | 86.704% |
| SynAct Pharma AB | 51.83 Million SEK | 79.652% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -32.683% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -103.024% |
| LIDDS AB (publ) | 3.75 Million SEK | -180.804% |
| Lipum AB (publ) | 7.53 Million SEK | -39.918% |
| BioInvent International AB (publ) | 90.45 Million SEK | 88.34% |
| Alzinova AB (publ) | 9.33 Million SEK | -13.032% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 94.192% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -487.904% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 42.971% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -174.805% |
| Simris Alg AB (publ) | 148.93 Million SEK | 92.919% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 85.17% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.813% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 17.239% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -45.275% |